Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Abstract: The present invention relates to a Bicycle toxin conjugate BT5528, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.

Abstract: The present invention relates to a Bicycle toxin conjugate BT8009, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof. In one embodiment, the pharmaceutical composition comprises BT8009, histidine, sucrose and Polysorbate 20. In another embodiment, the pharmaceutical composition is for use in treating an advanced solid tumor malignancy associated with Nectin-4-expression in a patient, preferably in combination with Nivolumab.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4.The invention also includes drug conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Abstract: A container closure includes a generally planar body having a product side and a customer side. The body includes a container opening. The container opening includes a shifted material line.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Abstract: A container closure includes a generally planar body having a product side and a customer side. The body includes a container opening. The container opening includes a shifted material line.

Abstract: A daily intake formulated for breastfeeding women containing iron, vitamin B6, iodine, vitamin D, and herbs and galactogogues that support milk production.

Abstract: A daily intake formulated for breastfeeding women containing iron, vitamin B6, iodine, vitamin D, and herbs and galactogogues that support milk production.

Abstract: An apparatus (7) for monitoring particles flowing in a stack (6), comprises: an electrical-interaction monitor (1) operable to provide a signal (300) resulting from electrical interaction of the particles with the monitor (1). a scattered-light monitor (10) operable to provide a signal (310) resulting from detection of light scattered from the particles, and a controller (320) arranged to alter the calibration of the electrical-interaction monitor 1 in response to changes in the relative magnitude of the electrical-interaction (signal 300) and the scattered-light signal (310).

Abstract: An instrument (10) for monitoring particles (67) flowing in a stack, includes: (a) a light source for providing a light beam (60); (b) a sensor/and (c) a probe housing. The housing comprises: (i) a mount (25); (ii) a proximal portion (30) including a first aperture (35) through which in use the light beam (60) exits; (iii) a distal portion (50), including a second aperture (55) through which the light beam (60) enters after having been scattered from particles (67) flowing in the stack, and a focusing mirror (70) arranged to reflect and focus the scattered light (90); (iv) a medial portion (40), connecting the distal portion (50) to the proximal portion (30); (v) a waveguide (80), passing from the distal portion (50) through the medial portion (40) and the proximal portion (30) to the sensor and arranged to guide to the sensor the light (90) reflected and focused by the focusing mirror (70).

Abstract: An instrument (10) for monitoring particles (67) flowing in a stack, includes: (a) a light source for providing a light beam (60); (b) a sensor/and (c) a probe housing. The housing comprises: (i) a mount (25); (ii) a proximal portion (30) including a first aperture (35) through which in use the light beam (60) exits; (iii) a distal portion (50), including a second aperture (55) through which the light beam (60) enters after having been scattered from particles (67) flowing in the stack, and a focusing mirror (70) arranged to reflect and focus the scattered light (90); (iv) a medial portion (40), connecting the distal portion (50) to the proximal portion (30); (v) a waveguide (80), passing from the distal portion (50) through the medial portion (40) and the proximal portion (30) to the sensor and arranged to guide to the sensor the light (90) reflected and focused by the focusing mirror (70).

Abstract: An apparatus (7) for monitoring particles flowing in a stack (6), comprises: an electrical-interaction monitor (1) operable to provide a signal (300) resulting from electrical interaction of the particles with the monitor (1). a scattered-light monitor (10) operable to provide a signal (310) resulting from detection of light scattered from the particles, and a controller (320) arranged to alter the calibration of the electrical-interaction monitor 1 in response to changes in the relative magnitude of the electrical-interaction (signal 300) and the scattered-light signal (310).

Abstract: A method of controlling a laser is provided for generating an optical output. The method includes the step of making a change to an electrical input to the laser so as to move the optical output of the laser towards a target frequency, and also includes the step of changing the temperature of the laser in relation to the change in the electrical input or the movement of the optical output. The method further includes the step of making further changes to the electrical input as the temperature of the laser is changed so as to maintain the optical output of the laser at the target frequency.